Aperiam Bio develops hyperfolding variants of proteins that significantly enhance expression, solubility, and specific activity, enabling the production of stable enzymes for various applications. Their technology addresses the instability of natural proteins in harsh conditions, ensuring over 68% activity retention in therapeutics and extending the shelf life of cosmetic ingredients.

Cellsonics offers the SimpleFlow system, an acoustic wave‑driven device that mechanically dissociates tissue without enzymes or heat, producing high‑viability single‑cell suspensions while preserving surface markers and native transcriptional states. The workflow completes in minutes with minimal hands‑on steps and integrates directly with scRNA‑seq and flow‑cytometry pipelines, enabling unbiased cellular profiling for research labs and core facilities.

Constructive.Bio utilizes a dual-technology platform that combines de novo genome synthesis and engineered translation to create programmable biomolecules with high fidelity. This approach addresses the limitations of traditional biomanufacturing by enabling the production of customized bioproducts, including phage-resistant strains and next-generation therapeutics.

Delix Therapeutics develops neuroplastogens, a novel class of compounds that promote neuroplasticity to enhance brain health. Their approach targets neuropsychiatric conditions by repairing neural circuits and improving mental function through safe and fast-acting treatments.

Epana Bio offers a high‑throughput single‑cell multi‑omics and AI platform that maps patient‑specific immune cell dysfunction in autoimmune diseases to identify druggable molecular targets. The system automates design of tailored biologics or small‑molecule candidates and integrates rapid preclinical validation, enabling pharma and biotech partners to develop mechanism‑based therapies with reduced side effects.

Freya Biosciences develops microbial immunotherapies that target immune dysregulation and inflammation associated with reproductive health conditions such as infertility, endometriosis, and preterm birth. By engineering live microbes to restore a healthy vaginal microbiome, the company aims to improve clinical outcomes for women undergoing IVF and those facing reproductive system disorders.

Glyphic Biotechnologies develops Protein Sequencing by Expansion (ProSE™), a novel technology for high-throughput proteome sequencing. This method achieves single-molecule sensitivity for accurate discrimination of all 20 amino acids and post-translational modifications (PTMs). The platform aims to provide unprecedented precision and scalability for advancing proteomics research and therapeutic development.

Inscripta provides the MAD7™ genome‑editing platform, an IP‑free CRISPR‑derived nuclease designed for high‑efficiency editing in microbial and cell‑based production strains. Through an open licensing program and compatible software tools, it enables industrial biotech and synthetic biology companies to rapidly develop and scale sustainable bio‑alternatives without royalty fees.

Lightcast provides Envisia, a high‑throughput platform that isolates thousands of single cells and directly measures functional behaviours such as biomolecule secretion, cell‑cell communication, and susceptibility to targeted killing. The system combines microfluidic isolation, sensitive detection, and an integrated analytics suite to generate quantitative functional profiles that support antibody discovery, cellular therapy development, and other translational research applications.

Matterworks has developed a Large Spectral Model (LSM) that utilizes AI to analyze unstructured biological data, revealing insights that are typically overlooked. This technology addresses the challenge of interpreting vast amounts of omic data, enabling more effective utilization of biological measurements in biotechnology.

ReAx develops a chemical proteomic platform that utilizes protein family-wide small molecule probes and a barcoded detection strategy to quantify protein activity states. This technology enables the discovery of small molecule therapeutics for oncology and immunological diseases, targeting previously intractable protein families.

Replay is a genome writing company utilizing high payload herpes simplex virus (HSV) technology to deliver up to 150kb of DNA for gene therapies targeting complex diseases. The company addresses the limitations of current genomic medicine by enabling the writing and installation of large genetic constructs, facilitating the treatment of conditions affecting the skin, eye, brain, and muscle.

Stipple Bio provides a high‑resolution epitope‑level discovery platform that maps thousands of molecular points on tumor and normal cells to identify tumor‑specific epitopes invisible to conventional antibody discovery. By delivering ultra‑fine epitope maps and comparative analytics, the company enables pharma, biotech, and academic researchers to design more selective oncology antibodies and biologics, expanding target space and accelerating candidate development.

Syndex Bio is a biotechnology platform that integrates molecular technologies and artificial intelligence to enhance the diagnosis and treatment of diseases. By providing advanced tools for biological discovery, the company aims to improve healthcare outcomes through more accurate and efficient disease management.

SyntheX utilizes its ToR _FLEx_ platform to engineer cells for drug discovery, enabling the identification of selective drugs that target previously inaccessible proteins. This approach addresses the limitation of existing drug discovery technologies, which can only access 15% of the proteome, by exploiting novel mechanisms of action to modulate protein interactions and levels.

Tasso provides a needle‑free, self‑administered blood collection system that lets patients draw capillary blood at home using single‑use Tasso+ or Tasso Mini devices. The company handles end‑to‑end logistics—including kit shipping, live remote guidance, prepaid return shipping, and a cloud portal or API for sample tracking and results—enabling healthcare providers and researchers to run decentralized trials and frequent at‑home sampling without in‑person phlebotomy.

Tessera Therapeutics is pioneering Gene Writing™, a genome engineering technology that enables precise alterations to the human genome to treat genetic diseases at their source. This platform addresses the need for permanent and potentially curative therapies by delivering therapeutic genetic modifications directly to targeted tissues without the use of viral vectors.

Type6 Therapeutics develops small-molecule kinase inhibitors that target disease-driving kinases in their OFF-states, preventing tumors from accessing escape routes and enhancing treatment durability. Their approach addresses the challenge of evasive tumor responses, offering potent and ultra-selective therapies for aggressive cancers.

VedaBio develops the CRISPR Cascade platform for molecular detection, enabling ultra-rapid and highly multiplexed analysis of nucleic acid targets. This technology provides high accuracy without requiring target amplification, significantly speeding up analytical reaction times. The platform offers rapid reprogramming for new targets, expanding possibilities across various diagnostic applications.